Author

Jan Marsal;; 1

1 Lund University

DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN’S DISEASE IN SUSTAINED, COMBINED CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL

Sine Buhl, Casper Steenholdt, Jens Frederik Dahlerup, Tobias Wirenfeldt Klausen, Mark Andrew Ainsworth, Jørgen Jahnsen, Jørn Brynskov, Ole Østergaard Thomsen, Katrine Risager Christensen, Akbar Molazahi, Natalia Pedersen, Niels Thorsgaard, Eva Efsen Dahl, Ida Vind, Hendrika Adriana Linda Kievit, Taina Sipponen, Jan Marsal;;

LONG-TERM OUTCOMES OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - THE SWEDISH PROSPECTIVE MULTICENTRE SVEAH EXTENSION STUDY

Isabella Visuri, Carl Eriksson, Sara Karlqvist, VYRON LYKIARDOPOULOS, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson

REAL-WORLD OUTCOMES OF TRANSITIONING FROM INTRAVENOUS TO SUBCUTANEOUS VEDOLIZUMAB TREATMENT: A NATIONWIDE COHORT BASED ON THE SWEDISH INFLAMMATORY BOWEL DISEASE QUALITY REGISTER

Nishan Lamichhane, Nikolaos Melas, Viktoria Bergqvist, Swibreg Sweden, Nils-Peter Ekholm, Ola Olén, Jonas F Ludvigsson, Henrik Hjortswang, Jan Marsal, Carl Eriksson, Jonas Halfvarson

Item 1 - 3 / 3
1